2 hours ago
3
Vandita Jadeja
Mon, May 25, 2026 astatine 6:47 AM CDT 4 min read
Quick Read
-
Johnson & Johnson (JNJ) reported Q1 2026 gross of $24.06 billion, beating expectations with 9.9% YoY maturation driven by TREMFYA surging 68.3% and DARZALEX climbing 22.5% to $3.96 billion, portion raising FY26 guidance to a midpoint of $100.8 billion.
-
AbbVie (ABBV) posted Q1 gross of $15 cardinal (+12.4% YoY) with Skyrizi reaching $4.48 cardinal (+30.9%) and Rinvoq adding $2.12 cardinal (+23.3%), much than offsetting Humira’s 38.6% diminution contempt a $744 cardinal IPR&D charge.
-
JNJ is diversifying done a DePuy Synthes spin-off and $1 cardinal compartment therapy manufacturing investment, portion AbbVie is concentrating maturation astir Skyrizi and Rinvoq immunology drugs and entering obesity attraction with ABBV-295 done a $1.4 cardinal North Carolina field investment.
-
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.
Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) some posted Q1 2026 results that bushed gross expectations and prompted raised full-year guidance. JNJ leaned connected a diversified pharma positive MedTech engine. AbbVie leaned astir wholly connected immunology. Both look biosimilar headwinds, yet each chose a antithetic mode to outgrow them.
TREMFYA and Cardiovascular Carry JNJ. Skyrizi Carries AbbVie.
JNJ delivered gross of $24.06 cardinal (+9.9% YoY) and adjusted EPS of $2.70, a 4th consecutive beat. Innovative Medicine led with 11.2% growth, powered by DARZALEX astatine $3.96 cardinal (+22.5%) and TREMFYA leaping 68.3% arsenic it absorbs STELARA patients.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and AbbVie wasn't 1 of them. Get them present FREE.
MedTech Cardiovascular climbed 13%, with Shockwave up 18.5%. CEO Joaquin Duato called the 4th "a beardown commencement to 2026", and the institution raised its FY26 gross outlook to a midpoint of $100.8 billion.
AbbVie reported $15 cardinal successful gross (+12.4%), but adjusted EPS of $2.65 narrowly missed statement aft a $744 cardinal IPR&D complaint clipped net by $0.41. Skyrizi reached $4.48 cardinal (+30.9%) and Rinvoq added $2.12 cardinal (+23.3%), much than offsetting Humira's 38.6% decline. CEO Robert Michael said the steadfast is "off to an fantabulous commencement successful 2026".
A Diversified Giant Meets a Concentrated Specialist
The strategical divided is meaningful. JNJ is sharpening absorption by spinning disconnected DePuy Synthes Orthopaedics and pouring implicit $1 cardinal into Pennsylvania compartment therapy manufacturing.
AbbVie is going the other way, broadening into obesity done ABBV-295, a non-incretin campaigner showing value simplification successful Phase 1, portion committing $1.4 cardinal to a North Carolina campus.
English (CA) · 
English (US) · 
Spanish (MX) ·